<div id="readability-page-1"><ul><li>Eli Lilly Posts Stellar Q3: Long-Term Upside Is Well in Play</li></ul><p>Eli Lilly and Company, Pfizer, Novo Nordisk A/S, 89BIO, McKesson, AbbVie,  and Teva Pharmaceutical Industries are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of companies that research, develop, manufacture, and sell prescription drugs, vaccines, and related therapies. For investors, these equities offer exposure to the pharmaceutical industry's revenue and growth potential but also carry risks tied to clinical trial results, regulatory approvals, patent expirations, and changing healthcare policies, which can cause significant volatility. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.</p><div><p><span></span><span>Get <strong>Eli Lilly and Company</strong> alerts:</span></p></div><h2>Eli Lilly and Company (LLY)</h2><p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p><ul><li>Got 1K to Invest? These 3 Stocks Are Still Attractive Buys</li></ul><p>Read Our Latest Research Report on LLY</p><h2>Pfizer (PFE)</h2><p>Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.</p><ul><li>Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead</li></ul><p>Read Our Latest Research Report on PFE</p><h2>Novo Nordisk A/S (NVO)</h2><p>Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.</p><p>Read Our Latest Research Report on NVO</p><h2>89BIO (ETNB)</h2><p>89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia.</p><p>Read Our Latest Research Report on ETNB</p><h2>McKesson (MCK)</h2><p>McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.</p><p>Read Our Latest Research Report on MCK</p><h2>AbbVie (ABBV)</h2><p>AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.</p><p>Read Our Latest Research Report on ABBV</p><h2>Teva Pharmaceutical Industries (TEVA)</h2><p>Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.</p><p>Read Our Latest Research Report on TEVA</p><h2>Featured Articles</h2><ul><li>MarketBeat's Top Five Stocks to Own in November 2025</li><li>Follow the Money: 3 Stocks With High Institutional Ownership</li><li>Can Gold Mining Stocks Shine as the Metals Rally Falters?</li><li>Dutch Bros Beats Earnings for 11th Consecutive Quarter</li><li>From Dividends to Growth: Why These 3 Stocks Stand Out in 2025</li><li>AMD’s Price Pullback Equals Opportunity: The Big Gains Are Coming</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ABBV

ETNB

<p>Eli Lilly, Pfizer, Novo Nordisk, 89BIO, McKesson, AbbVie, and Teva Pharmaceutical Industries are highlighted as top pharmaceutical stocks to watch, according to MarketBeat. These companies are involved in the research, development, and sale of pharmaceuticals, offering growth potential but also facing risks from clinical trials and regulatory changes. Eli Lilly recently reported strong Q3 results, indicating long-term upside. Investors are advised to consider these stocks for potential investment opportunities.</p>

Top Pharmaceutical Stocks To Add to Your Watchlist - November 6th